In the phase III PIVOT IO 001 trial reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues found that the addition of bempegaldesleukin, a pegylated interleukin-2 cytokine prodrug, to nivolumab did not improve treatment outcomes in previously untreated patients with advanced melanoma.
2023
CDKN2A Mutation and Higher Nevus Count Can Increase Risk for Subsequent Primary Melanoma
There is a high certainty of evidence that patients with CDKN2A mutation and a moderate or high nevus count had significantly increased risk for multiple primary melanomas, according to study results published in the British Journal of Dermatology.
Novel Intercellular Signaling Mechanisms Promote Melanoma Growth
Investigators led by Kathleen Green, PhD, the Joseph L. Mayberry, Sr., Professor of Pathology and Toxicology, have discovered novel intercellular “crosstalk” between epidermal keratinocytes and melanoma cells that promote cancer growth and metastasis.
Phase 2 SCOPE Trial of SCIB1 Achieves Positive ORR in Advanced Melanoma
Positive objective response results were demonstrated in the first stage of the phase 2 SCOPE trial. Now, 27 additional patients with advanced melanoma will be treated with SCIB1 and checkpoint inhibitors in stage 2.